{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T06:30:59Z","timestamp":1648967459838},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.1007\/s11926-002-0049-2","type":"journal-article","created":{"date-parts":[[2007,6,2]],"date-time":"2007-06-02T08:53:27Z","timestamp":1180774407000},"page":"449-451","source":"Crossref","is-referenced-by-count":0,"title":["Clinical trials for pediatric scleroderma"],"prefix":"10.1007","volume":"4","author":[{"given":"Margalit E.","family":"Rosenkranz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J. A.","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"49_CR1","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0031-3955(16)40058-1","volume":"42","author":"Y Uziel","year":"1995","unstructured":"Uziel Y, Miller ML: Scleroderma in children. Pediatr Clin North Am 1995, 42:1171\u20131203.","journal-title":"Pediatr Clin North Am"},{"key":"49_CR2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/00002281-199611000-00013","volume":"8","author":"TJA Lehman","year":"1996","unstructured":"Lehman TJA: Systemic and localized scleroderma in children. Curr Opin Rheum 1996, 8:576\u2013579.","journal-title":"Curr Opin Rheum"},{"key":"49_CR3","first-page":"1573","volume":"28","author":"EC LeRoy","year":"2001","unstructured":"LeRoy EC, Medsger TA: Criteria for the classification of early systemic sclerosis. J Rheumatol 2001, 28:1573\u20131576.","journal-title":"J Rheumatol"},{"key":"49_CR4","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","volume":"43","author":"VD Steen","year":"2000","unstructured":"Steen VD, Medsger TA: Severe organ involvement in Systemic Sclerosis with diffuse scleroderma. Arthritis Rheum 2000, 43:2437\u20132444.","journal-title":"Arthritis Rheum"},{"key":"49_CR5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/rheumatology\/39.5.556","volume":"39","author":"I Foeldvari","year":"2000","unstructured":"Foeldvari I, Zhavania M, Birdi N, et al.: Favorable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey. Rheumatology 2000, 39:556\u2013559.","journal-title":"Rheumatology"},{"key":"49_CR6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00002281-200111000-00010","volume":"13","author":"CP Denton","year":"2001","unstructured":"Denton CP, Abraham DJ:Transforming growth factor-[beta] and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rhuem 2001, 13:505\u2013511.","journal-title":"Curr Opin Rhuem"},{"key":"49_CR7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1563-2571.2002.01038.x","volume":"29","author":"GH Strummvoll","year":"2002","unstructured":"Strummvoll GH:Current treatment options in systemic sclerosis (scleroderma). Acta Medica Austraica 2002, 29:14\u201319.","journal-title":"Acta Medica Austraica"},{"key":"49_CR8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11926-996-0008-4","volume":"3","author":"A Martini","year":"2001","unstructured":"Martini A: Juvenile systemic scleroderma. Current Rheum Rep 2001, 3:387\u2013390. Outstanding review of pediatric scleroderma. Offers information on the role of microchimerism in the pathogenesis of PSS.","journal-title":"Current Rheum Rep"},{"key":"49_CR9","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7","volume":"42","author":"PJ Clements","year":"1999","unstructured":"Clements PJ, Furst DE, Wong WK, et al.: High dose versus low dose D-penicillamine in early diffuse systemic sclerosis: analysis of a 2 year, double blind, randomized controlled clinical trial. Arthritis Rheum 1999, 42:1194\u2013203.","journal-title":"Arthritis Rheum"},{"key":"49_CR10","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/1529-0131(200112)44:12<2828::AID-ART470>3.0.CO;2-U","volume":"12","author":"VD Steen","year":"2001","unstructured":"Steen VD, Medsger TA: Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001, 12:2828\u20132835.","journal-title":"Arthritis Rheum"},{"key":"49_CR11","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q","volume":"11","author":"PJ Clements","year":"2000","unstructured":"Clements PJ, Hurvitz EL, Furst DE: Skin thickness core as a predictor and correlate of outcome in systemic sclerosis: high dose versus low dose penicillamine trial. Arthritis Rheum 2000, 11:2445\u20132454.","journal-title":"Arthritis Rheum"},{"key":"49_CR12","first-page":"1496","volume":"18","author":"SA Jimenez","year":"1991","unstructured":"Jimenez SA, Sigal SH: A 15-year prospective study of the treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheumatol 1991, 18:1496\u2013503.","journal-title":"J Rheumatol"},{"key":"49_CR13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/030097401316909503","volume":"30","author":"TA Medsger","year":"2001","unstructured":"Medsger TA, Lucas M: D-Penicillamine in systemic sclerosis? Yes! Scand J Rheumatol 2001, 30:192\u2013194.","journal-title":"Scand J Rheumatol"},{"key":"49_CR14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/030097401316909495","volume":"30","author":"DE Furst","year":"2001","unstructured":"Furst DE, Clements PJ: D-penicillamine is not an effective treatment in systemic sclerosis. Scand J Rheumatol 2001, 30:189\u2013191.","journal-title":"Scand J Rheumatol"},{"key":"49_CR15","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","volume":"44","author":"JE Pope","year":"2001","unstructured":"Pope JE, Bellamy N, Seibold JR, et al.: A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001, 44:1351\u20131358. Outstanding review of pediatric scleroderma. Offers information on the role of microchimerism in the pathogenesis of PSS.","journal-title":"Arthritis Rheum"},{"key":"49_CR16","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/art.10088","volume":"46","author":"TJA Lehman","year":"2002","unstructured":"Lehman TJA: Methotrexate for the treatment of early diffuse scleroderma. Arthritis Rhem 2002, 46:845.","journal-title":"Arthritis Rhem"},{"key":"49_CR17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.1780360113","volume":"36","author":"PJ Clements","year":"1993","unstructured":"Clements PJ, Lachenbruch PA, Stertz M, et al.: Cyclosporin in systemic sclerosis: results of a forty eight-week open study in ten patients. Arthritis Rheum 1993, 36:75\u201383.","journal-title":"Arthritis Rheum"},{"key":"49_CR18","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/rheumatology\/40.12.1431","volume":"40","author":"G Filachi","year":"2001","unstructured":"Filachi G, Cutolo M, Indiveri F, et al.:Long term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology 2001, 40:1431\u20131432.","journal-title":"Rheumatology"},{"key":"49_CR19","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-132-12-200006200-00004","volume":"132","author":"B White","year":"2000","unstructured":"White B, Moore W, Wigley F, et al.:Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000, 132:947\u2013954. A retrospective study that shows beneficial effects of cyclophosphamide in scleroderma-related interstitial lung disease.","journal-title":"Ann Intern Med"},{"key":"49_CR20","first-page":"731","volume":"29","author":"R Giacomelli","year":"2002","unstructured":"Giacomelli R, Valentini G, Salsano F, et al.:Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002, 29:731\u2013736.","journal-title":"J Rheumatol"},{"key":"49_CR21","first-page":"298","volume":"29","author":"I Pakas","year":"2002","unstructured":"Pakas I, Ioannidis JPA, Malagari K, et al.:Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002, 29:298\u2013304.","journal-title":"J Rheumatol"},{"key":"49_CR22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1006\/clim.2000.4920","volume":"97","author":"SJ Oliver","year":"2000","unstructured":"Oliver SJ, Moreira A, Kaplan G:Immune stimulation in scleroderma patients treated with thalidomide. Clin Immunol 2000, 97:109\u2013120.","journal-title":"Clin Immunol"},{"key":"49_CR23","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00002281-200205000-00004","volume":"14","author":"DE Furst","year":"2002","unstructured":"Furst DE:Stem cell transplantation for autoimmune disease: progress and problems. Curr Opin Rheumatol 2002, 14:220\u2013224.","journal-title":"Curr Opin Rheumatol"},{"key":"49_CR24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/ar102","volume":"2","author":"A Tyndall","year":"2000","unstructured":"Tyndall A, Gratwohl A: Immune ablation and stem-cell therapy in autoimmune disease: a clinical experience. Arthritis Res 2000, 2:276\u2013280.","journal-title":"Arthritis Res"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-002-0049-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-002-0049-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-002-0049-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:47:09Z","timestamp":1559422029000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-002-0049-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["49"],"URL":"https:\/\/doi.org\/10.1007\/s11926-002-0049-2","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12]]}}}